KRYS vs RCKT
KRYS: Krystal Biotech is a commercial-stage gene therapy company using its proprietary STAR-D platform to treat rare diseases with targeted, redosable genetic medicines. RCKT: Rocket Pharmaceuticals is a clinical-stage biotechnology company developing transformative gene therapies for rare, high-unmet-need genetic disorders.
Side-by-side fundamentals
| Metric | KRYS | RCKT | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $326.45 | $3.61 | |
| Market cap as of 2026-08-10 | $9.7B | $394M | |
| P/E as of 2026-08-10 | 42.94 | n/a | |
| PEG as of 2026-08-10 | 0.78 | n/a | |
| Net margin as of 2026-08-10 | +53.9% | n/a | |
| Gross margin as of 2026-08-10 | +94.2% | n/a | |
| Operating margin as of 2026-08-10 | +42.8% | n/a | |
| ROE as of 2026-08-10 | +19.3% | -70.8% | KRYS higher |
| ROA as of 2026-08-10 | +17.6% | -59.6% | KRYS higher |
| Debt / equity as of 2026-08-10 | 0.00 | 0.09 | KRYS lower |
| Revenue growth (YoY) as of 2026-08-10 | +25.1% | n/a | |
| Beta as of 2026-08-10 | 0.47 | 0.46 | |
| 1-year return as of 2026-08-07 close | +139.9% | +16.8% | KRYS higher |
Fundamentals: market data, as of 2026-08-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.